110 related articles for article (PubMed ID: 11853121)
41. Cannabinoid exposure in pubertal rats increases spontaneous ethanol consumption and NMDA receptor associated protein levels.
Klugmann M; Klippenstein V; Leweke FM; Spanagel R; Schneider M
Int J Neuropsychopharmacol; 2011 May; 14(4):505-17. PubMed ID: 21211107
[TBL] [Abstract][Full Text] [Related]
42. Antinociceptive effect of the cannabinoid agonist, WIN 55,212-2, in the orofacial and temporomandibular formalin tests.
Burgos E; Pascual D; Martín MI; Goicoechea C
Eur J Pain; 2010 Jan; 14(1):40-8. PubMed ID: 19318283
[TBL] [Abstract][Full Text] [Related]
43. Large receptor reserve for cannabinoid actions in the central nervous system.
Gifford AN; Bruneus M; Gatley SJ; Lan R; Makriyannis A; Volkow ND
J Pharmacol Exp Ther; 1999 Feb; 288(2):478-83. PubMed ID: 9918548
[TBL] [Abstract][Full Text] [Related]
44. CB1 receptor agonist and heroin, but not cocaine, reinstate cannabinoid-seeking behaviour in the rat.
Spano MS; Fattore L; Cossu G; Deiana S; Fadda P; Fratta W
Br J Pharmacol; 2004 Oct; 143(3):343-50. PubMed ID: 15339858
[TBL] [Abstract][Full Text] [Related]
45. Electrophysiological effects of a cannabinoid on neural activity in the globus pallidus.
Miller AS; Walker JM
Eur J Pharmacol; 1996 May; 304(1-3):29-35. PubMed ID: 8813581
[TBL] [Abstract][Full Text] [Related]
46. In vitro autoradiography of receptor-activated G proteins in rat brain by agonist-stimulated guanylyl 5'-[gamma-[35S]thio]-triphosphate binding.
Sim LJ; Selley DE; Childers SR
Proc Natl Acad Sci U S A; 1995 Aug; 92(16):7242-6. PubMed ID: 7638174
[TBL] [Abstract][Full Text] [Related]
47. Inhibitory effect of cannabinoid agonists on gastric emptying in the rat.
Izzo AA; Mascolo N; Capasso R; Germanò MP; De Pasquale R; Capasso F
Naunyn Schmiedebergs Arch Pharmacol; 1999 Aug; 360(2):221-3. PubMed ID: 10494894
[TBL] [Abstract][Full Text] [Related]
48. The neurobiology of cannabinoid analgesia.
Walker JM; Hohmann AG; Martin WJ; Strangman NM; Huang SM; Tsou K
Life Sci; 1999; 65(6-7):665-73. PubMed ID: 10462067
[TBL] [Abstract][Full Text] [Related]
49. Behavioral effects of cannabinoids show differential sensitivity to cannabinoid receptor blockade and tolerance development.
De Vry J; Jentzsch KR; Kuhl E; Eckel G
Behav Pharmacol; 2004 Feb; 15(1):1-12. PubMed ID: 15075621
[TBL] [Abstract][Full Text] [Related]
50. Pharmacologic interaction between cannabinoid and either clonidine or neostigmine in the rat formalin test.
Yoon MH; Choi JI
Anesthesiology; 2003 Sep; 99(3):701-7. PubMed ID: 12960556
[TBL] [Abstract][Full Text] [Related]
51. Behavioral sensitization to WIN55212.2 in rats pretreated with heroin.
Pontieri FE; Monnazzi P; Scontrini A; Buttarelli FR; Patacchioli FR
Brain Res; 2001 Apr; 898(1):178-80. PubMed ID: 11292463
[TBL] [Abstract][Full Text] [Related]
52. Acetylcholine/dopamine interaction in planaria.
Buttarelli FR; Pontieri FE; Margotta V; Palladini G
Comp Biochem Physiol C Toxicol Pharmacol; 2000 Feb; 125(2):225-31. PubMed ID: 11790344
[TBL] [Abstract][Full Text] [Related]
53. Effects of neuropeptide FF system on CB₁ and CB₂ receptors mediated antinociception in mice.
Fang Q; Han ZL; Li N; Wang ZL; He N; Wang R
Neuropharmacology; 2012 Feb; 62(2):855-64. PubMed ID: 21945715
[TBL] [Abstract][Full Text] [Related]
54. Cannabinoid agonists stimulate [3H]GABA release in the globus pallidus of the rat when G(i) protein-receptor coupling is restricted: role of dopamine D2 receptors.
Gonzalez B; Paz F; Florán L; Aceves J; Erlij D; Florán B
J Pharmacol Exp Ther; 2009 Mar; 328(3):822-8. PubMed ID: 19106171
[TBL] [Abstract][Full Text] [Related]
55. Effects of cannabinoids on dopamine release in the corpus striatum and the nucleus accumbens in vitro.
Szabo B; Müller T; Koch H
J Neurochem; 1999 Sep; 73(3):1084-9. PubMed ID: 10461898
[TBL] [Abstract][Full Text] [Related]
56. Antagonism between the anti-inflammatory activity of the cannabinoid WIN 55212-2 and SR 141716A.
Pozzi O; Misiano P; Clark GD; Visentin L
Pharmacology; 2003 Nov; 69(3):158-63. PubMed ID: 14512703
[TBL] [Abstract][Full Text] [Related]
57. Systemic administration of WIN 55,212-2 increases norepinephrine release in the rat frontal cortex.
Oropeza VC; Page ME; Van Bockstaele EJ
Brain Res; 2005 Jun; 1046(1-2):45-54. PubMed ID: 15927549
[TBL] [Abstract][Full Text] [Related]
58. Antiemetic and motor-depressive actions of CP55,940: cannabinoid CB1 receptor characterization, distribution, and G-protein activation.
Darmani NA; Sim-Selley LJ; Martin BR; Janoyan JJ; Crim JL; Parekh B; Breivogel CS
Eur J Pharmacol; 2003 Jan; 459(1):83-95. PubMed ID: 12505537
[TBL] [Abstract][Full Text] [Related]
59. Effect of the cannabinoid receptor agonist WIN55212-2 on sympathetic cardiovascular regulation.
Niederhoffer N; Szabo B
Br J Pharmacol; 1999 Jan; 126(2):457-66. PubMed ID: 10077239
[TBL] [Abstract][Full Text] [Related]
60. Cannabinoid agonist-induced sensitisation to morphine place preference in mice.
Manzanedo C; Aguilar MA; Rodríguez-Arias M; Navarro M; Miñarro J
Neuroreport; 2004 Jun; 15(8):1373-7. PubMed ID: 15167569
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
